4.6 Editorial Material

Comment on Herring et al. The Use of Retardation in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044 Comment

Journal

CELLS
Volume 11, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/cells11121937

Keywords

gene nomenclature; HGNC; fragile X syndrome; FMR1; FRAXA

Categories

Funding

  1. National Human Genome Research Institute (NHGRI) [U24HG003345]
  2. Wellcome Trust [208349/Z/17/Z]
  3. Wellcome Trust [208349/Z/17/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

This commentary responds to a recent article by Herring et al. discussing the eradication of the offensive term "retardation" from gene naming. The commentary outlines the actions taken by the HUGO Gene Nomenclature Committee (HGNC) to remove this term from gene names and highlights the latest naming changes made in collaboration with the authors and the European Fragile X Network.
This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term retardation from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken to remove this term from our gene names. We also highlight the latest nomenclature changes made as a result of discussions with the authors and agreement with the European Fragile X Network.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available